Industry leaders are exploring alternative IP strategies that can fuel creativity in psychedelic medicine.
The company has closed a $39 million round of financing to optimize existing substances, which they say will make them safer and more effective.
Entrepreneurs opening psilocybin businesses in Oregon face difficulties finding liability insurance and sympathetic landlords.
The company has launched a Community Stakeholder Initiative that allows more people to invest in next-generation MDMA-like medicines.
As psilocybin businesses prepare to open under state law next year, entrepreneurs are looking to lawyers to help them navigate complex and challenging regulatory requirements.
The drug development company inspires psychedelics experts, but struggles to raise funds for its ketamine-assisted therapies and addiction treatments.
Enthea will provide psychedelic health care benefits through employers, with plans to expand across 40 states.
The founder of two leading psychedelic science companies and an influential nonprofit is shaping research, as well as efforts to patent it.
Eleusis’ IV form of psilocin will see clinical trials, but Eleusis-backed research into the anti-inflammatory properties of psychedelics is uncertain.
The acquisition is the latest sign of stress among startups in the sector, which has seen valuations plummet.